Episode 114: Saku Biosciences: Mark van Zee on Raising Friends-and-Family in a Frozen Market, Betting on the Jockey, and Giving a VC Goosebumps in Five Minutes
In this episode, I sit down with Mark van Zee, Co-Founder & CEO of Saku Biosciences, who just closed a $940K round with Big Idea Ventures coming in as the institutional lead. It's a refreshingly different conversation for this show — instead of a later-stage playbook, Mark takes us all the way back to the very first checks, and how you actually raise when the market is frozen. Saku started fundraising two weeks after the tariff announcement that sent institutional capital "to zero," so Mark and his co-founder John got scrappy: friends-and-family checks of $5K–$100K that triggered a "pile-on" chain reaction, plus capital from a non-obvious private institution that took a year of relationship-building and ultimately saved the company. Mark reframes friends-and-family money not as a source of anxiety but as motivation — a commitment "in blood" — and makes the case that early-stage investing is betting on the jockey, not the horse. We close on one of the best fundraising stories I've heard: how the Saku team reverse-engineered exactly what Big Idea Ventures' decision-maker was looking for ("something that gives me goosebumps") and built a five-minute narrative to deliver it.
🎧 Listen to the full episode to hear why fundraising is more like dating than a transaction, how to unlock non-obvious capital that isn't promoted anywhere, why you sell to the associate and the partner completely differently, how Mark turned "I ride my bike to college classes at fourteen" into a goosebumps pitch, and why nobody in food tech has cracked the scalable-company code yet — but the wave is coming.
Funding: $940K round (SAFE), with Big Idea Ventures as institutional lead (Global Food Innovation Fund II) — following a friends-and-family raise and capital from a private institutional source.
Blurb
SAKU BIOSCIENCES exists to fix a quiet but expensive failure in biomanufacturing: the strains companies screen in the lab are optimized for the lab, not for the fermentation tank they'll actually run in. That mismatch produces false positives, wasted scale-up campaigns, and stubbornly poor unit economics. Saku's PicoShells platform — hollow, porous hydrogel particles that isolate millions of strain variants and let them be tested under true bioreactor conditions — lets producers select for real-world manufacturing performance, and get to the cost parity that fermentation needs to displace incumbent animal- and plant-derived inputs.
Podden och tillhörande omslagsbild på den här sidan tillhör
Alex Shandrovsky. Innehållet i podden är skapat av Alex Shandrovsky och inte av,
eller tillsammans med, Poddtoppen.
